Ignite Creation Date:
2025-12-24 @ 5:56 PM
Ignite Modification Date:
2025-12-25 @ 3:19 PM
Study NCT ID:
NCT05862168
Status:
RECRUITING
Last Update Posted:
2023-07-17
First Post:
2023-05-07
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Neoadjuvant Treatment of Tislelizumab Combined Chemotherapy for Locally Advanced Oral Squamous Cell Carcinoma ：A Single-arm, Prospective, Phase II Trial
Sponsor:
Weijia Fang, MD
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2023-05-08
Start Date Type:
ACTUAL
Primary Completion Date:
2024-06-30
Primary Completion Date Type:
ESTIMATED
Completion Date:
2028-06-30
Completion Date Type:
ESTIMATED
First Submit Date:
2023-05-07
First Submit QC Date:
None
Study First Post Date:
2023-05-17
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-07-14
Last Update Post Date:
2023-07-17
Last Update Post Date Type:
ACTUAL